International coding of acupoints

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Acupoint | International coding | Acupoint | International coding | Acupoint | International coding |
| Jianliao | TE14 | Guanyuan | CV4 | Taiyang | EX-HN5 |
| Quchi | LI11 | Qihai | CV6 | Wangu | SI4 |
| Hegu | LI4 | Jianzhen | SI9 | Yamen | GV15 |
| Huantiao | GB30 | Naoshu | SI10 | Daying | ST5 |
| Yanlingquan | GB34 | Bingfeng | SI12 | Jinjin | EX-HN12 |
| Zusanli | ST36 | Tianzong | SI11 | Zhibian | BL54 |
| Xuanzhong | GB39 | Quyuan | SI13 | Xiyan | EX-LE5 |
| Jiexi | ST41 | Jianwaishu | SI14 | Zhongfeng | LR4 |
| Kunlun | BL60 | Jianzhongshu | SI15 | Yifeng | SJ17 |
| Taichong | LR3 | Jianyu | LI15 | Shenting | GV24 |
| Dicang | ST4 | Biguan | ST31 | Waiguan | TE5 |
| Yingxiang | LI20 | Xuehai | SP10 | Tianjin | TE10 |
| Jiachengjiang | EX-HN9 | Fengshi | GB31 | Naohui | TE13 |
| Lianquan | CV23 | Fenglong | ST40 | Weizhong | BL40 |
| Fengchi | GB20 | Baihui | GV20 | Chengshan | BL57 |
| Fengfu | GV16 | Renying | ST9 | Shangjuxu | ST37 |
| Taixi | KI3 | Houxi | SI3 | Sishencong | EX-HN1 |
| Shenshu | BL23 | Juegu |  | Xuanli | GB6 |
| Huatuojiaji |  | Sanyinjiao | SP6 | Qubin | GB7 |
| Renzhong | GV26 | Jiquan | HT1 | Dazhui | GV14 |
| Shousanli | LI10 | Chize | LU5 | Neiting | ST44 |
| Neiguan | PC6 | Xinshu | BL15 | Cuanzhu | BL2 |
| Shaoze | SI1 | Geshu | BL17 | Yangbai | GB14 |
| Tiantu | CV22 | Shaohai | HT3 | Yintang | GV29 |
| Tianfu | LU3 | Yongquan | KI1 | Baxie | EX-UE9 |
| Yangchi | TE4 | Shuigou | GV26 | Shenmen | HT7 |
| Danshu | BL19 | Jianqia | EX-UE12 | Futu | ST32 |
| Tongli | HT5 | Lieque | LU7 | Qiuxu | GB40 |
| Qianzheng | EX-HN10 | Jianqian | EX-UE12 | Sishen | EX-HN1 |
| Jingming | BL1 | Cuanzhu | BL2 | Sibai | ST2 |
| Chengjiang | CV24 |  |  |  |  |

**GRADE evidence profile**

**Author(s)**:

**Question**: TCM combined With routine treatment compared to routine treatment for Stroke

**Setting**:

**Bibliography**: . TCM for Stroke. Cochrane Database of Systematic Reviews [Year], Issue [Issue].

| **Certainty assessment** | **№ of patients** | **Effect** | **Certainty** | **Importance** |
| --- | --- | --- | --- | --- |
| **№ of studies** | **Study design** | **Risk of bias** | **Inconsistency** | **Indirectness** | **Imprecision** | **Other considerations** | **TCM combined With routine treatment** | **routine treatment** | **Relative(95% CI)** | **Absolute(95% CI)** |
| **TER** |
| 36  | randomised trials  | not serious  | not serious  | not serious  | not serious  | none  | 1758/1922 (91.5%)  | 1276/1739 (73.4%)  | **OR 4.03**(3.30 to 4.91)  | **184 more per 1,000**(from 167 more to 197 more)  | ⨁⨁⨁⨁HIGH  | CRITICAL  |
| **TCMs-TER** |
| 12  | randomised trials  | not serious  | not serious  | not serious  | not serious  | none  | 693/776 (89.3%)  | 459/625 (73.4%)  | **OR 3.08**(2.27 to 4.18)  | **161 more per 1,000**(from 128 more to 186 more)  | ⨁⨁⨁⨁HIGH  | CRITICAL  |
| **ACU-TER** |
| 18  | randomised trials  | not serious  | not serious  | not serious  | not serious  | none  | 831/894 (93.0%)  | 641/865 (74.1%)  | **OR 4.60**(3.41 to 6.21)  | **188 more per 1,000**(from 166 more to 206 more)  | ⨁⨁⨁⨁HIGH  | CRITICAL  |
| **OTTCM-TER** |
| 6  | randomised trials  | serious a | not serious  | not serious  | not serious  | none  | 234/252 (92.9%)  | 176/249 (70.7%)  | **OR 5.67**(3.24 to 9.93)  | **225 more per 1,000**(from 180 more to 253 more)  | ⨁⨁⨁◯MODERATE  | CRITICAL  |
| **NIHSS** |
| 21  | randomised trials  | not serious  | serious b | not serious  | not serious  | none  | 1069  | 1062  | -  | MD **3.28 lower**(3.97 lower to 2.58 lower)  | ⨁⨁⨁◯MODERATE  | CRITICAL  |
| **TCMs-NIHSS** |
| 11  | randomised trials  | not serious  | serious b | not serious  | not serious  | none  | 610  | 610  | -  | MD **2.54 lower**(3.2 lower to 1.88 lower)  | ⨁⨁⨁◯MODERATE  | CRITICAL  |
| **ACU-NIHSS** |
| 8  | randomised trials  | not serious  | serious b | not serious  | not serious  | none  | 371  | 364  | -  | MD **4.76 lower**(7.22 lower to 2.3 lower)  | ⨁⨁⨁◯MODERATE  | CRITICAL  |
| **OTTCM-NIHSS** |
| 2  | randomised trials  | serious a | serious b | not serious  | not serious  | publication bias strongly suspected c | 88  | 88  | -  | MD **3.4 lower**(7.45 lower to 0.65 higher)  | ⨁◯◯◯VERY LOW  | CRITICAL  |
| **Barthel** |
| 26  | randomised trials  | not serious  | serious b | not serious  | not serious  | none  | 1168  | 1152  | -  | MD **11.56 higher**(9.45 higher to 13.67 higher)  | ⨁⨁⨁◯MODERATE  | CRITICAL  |
| **TCMs-Barthel** |
| 6  | randomised trials  | not serious  | not serious  | not serious  | not serious  | none  | 306  | 306  | -  | MD **11.08 higher**(9.85 higher to 12.3 higher)  | ⨁⨁⨁⨁HIGH  | CRITICAL  |
| **ACU- Barthel** |
| 12  | randomised trials  | not serious  | serious b | not serious  | not serious  | none  | 556  | 548  | -  | MD **13.27 higher**(9.73 higher to 16.81 higher)  | ⨁⨁⨁◯MODERATE  | CRITICAL  |
| **OTTCM -Barthel** |
| 8  | randomised trials  | not serious  | serious b | not serious  | not serious  | none  | 306  | 298  | -  | MD **9.24 higher**(5.57 higher to 12.92 higher)  | ⨁⨁⨁◯MODERATE  | CRITICAL  |
| **FMA** |
| 24  | randomised trials  | not serious  | serious b | not serious  | not serious  | none  | 1028  | 1001  | -  | MD **12.33 higher**(9.84 higher to 14.82 higher)  | ⨁⨁⨁◯MODERATE  | CRITICAL  |
| **ACU - FMA** |
| 13  | randomised trials  | not serious  | serious b | not serious  | not serious  | none  | 618  | 606  | -  | MD **13 higher**(9.73 higher to 16.26 higher)  | ⨁⨁⨁◯MODERATE  | CRITICAL  |
| **OTTCM- FMA** |
| 11  | randomised trials  | not serious  | serious b | not serious  | not serious  | none  | 410  | 395  | -  | MD **11.56 higher**(7.88 higher to 15.24 higher)  | ⨁⨁⨁◯MODERATE  | CRITICAL  |
| **TC** |
| 7  | randomised trials  | not serious  | serious b | not serious  | not serious  | none  | 436  | 416  | -  | MD **0.54 lower**(0.8 lower to 0.28 lower)  | ⨁⨁⨁◯MODERATE  | CRITICAL  |
| **TG** |
| 7  | randomised trials  | not serious  | serious b | not serious  | not serious  | none  | 436  | 416  | -  | MD **0.48 lower**(0.64 lower to 0.31 lower)  | ⨁⨁⨁◯MODERATE  | CRITICAL  |
| **LDL** |
| 5  | randomised trials  | not serious  | serious b | not serious  | not serious  | none  | 326  | 308  | -  | MD **0.81 lower**(1.19 lower to 0.42 lower)  | ⨁⨁⨁◯MODERATE  | CRITICAL  |
| **HDL** |
| 5  | randomised trials  | not serious  | serious b | not serious  | not serious  | none  | 326  | 308  | -  | MD **0.24 higher**(0.09 higher to 0.38 higher)  | ⨁⨁⨁◯MODERATE  | CRITICAL  |
| **WHV** |
| 2  | randomised trials  | serious a | not serious  | not serious  | not serious  | none  | 110  | 108  | -  | MD **0.89 lower**(1.04 lower to 0.74 lower)  | ⨁⨁⨁◯MODERATE  | CRITICAL  |
| **WLV** |
| 2  | randomised trials  | serious a | serious b | not serious  | not serious  | none  | 110  | 108  | -  | MD **2.3 lower**(4.24 lower to 0.36 lower)  | ⨁⨁◯◯LOW  | CRITICAL  |
| **PV** |
| 2  | randomised trials  | serious a | serious b | not serious  | not serious  | none  | 110  | 108  | -  | MD **0.49 lower**(0.68 lower to 0.31 lower)  | ⨁⨁◯◯LOW  | CRITICAL  |
| **HCT** |
| 3  | randomised trials  | serious a | serious b | not serious  | not serious  | none  | 168  | 168  | -  | MD **2.65 lower**(4.71 lower to 0.58 lower)  | ⨁⨁◯◯LOW  | CRITICAL  |
| **FIB** |
| 9  | randomised trials  | not serious  | not serious  | not serious  | not serious  | none  | 496  | 479  | -  | MD **0.39 lower**(0.49 lower to 0.28 lower)  | ⨁⨁⨁⨁HIGH  | CRITICAL  |
| **HCY** |
| 7  | randomised trials  | not serious  | serious b | not serious  | not serious  | none  | 359  | 360  | -  | MD **4.38 lower**(6.13 lower to 2.63 lower)  | ⨁⨁⨁◯MODERATE  | CRITICAL  |
| **hs-CRP** |
| 5  | randomised trials  | not serious  | serious b | not serious  | not serious  | publication bias strongly suspected c | 225  | 226  | -  | MD **0.78 lower**(1.32 lower to 0.23 lower)  | ⨁⨁◯◯LOW  | CRITICAL  |
| **IgA** |
| 1  | randomised trials  | not serious  | serious d | not serious  | not serious  | none  | 60  | 60  | -  | MD **0.77 lower**(1.09 lower to 0.45 lower)  | ⨁⨁⨁◯MODERATE  | IMPORTANT  |
| **IgG** |
| 1  | randomised trials  | not serious  | serious d | not serious  | not serious  | none  | 60  | 60  | -  | MD **1.87 lower**(2.51 lower to 1.23 lower)  | ⨁⨁⨁◯MODERATE  | IMPORTANT  |
| **IgM** |
| 1  | randomised trials  | not serious  | serious d | not serious  | not serious  | none  | 60  | 60  | -  | MD **0.91 lower**(1.23 lower to 0.59 lower)  | ⨁⨁⨁◯MODERATE  | IMPORTANT  |
| **BFGF** |
| 1  | randomised trials  | not serious  | serious d | not serious  | serious e | none  | 46  | 46  | -  | MD **3.9 higher**(2.86 higher to 4.94 higher)  | ⨁⨁◯◯LOW  | IMPORTANT  |
| **VEGF** |
| 1  | randomised trials  | not serious  | serious d | not serious  | serious e | none  | 46  | 46  | -  | MD **272.24 higher**(261.12 higher to 283.36 higher)  | ⨁⨁◯◯LOW  | IMPORTANT  |
| **VFSS** |
| 2  | randomised trials  | serious a | serious b | not serious  | not serious  | none  | 60  | 60  | -  | MD **2.44 higher**(1.74 higher to 3.14 higher)  | ⨁⨁◯◯LOW  | IMPORTANT  |
| **SSA** |
| 1  | randomised trials  | serious a | serious d | not serious  | serious e | none  | 30  | 30  | -  | MD **3.4 lower**(4.99 lower to 1.81 lower)  | ⨁◯◯◯VERY LOW  | IMPORTANT  |
| **CSI** |
| 1  | randomised trials  | serious a | serious d | not serious  | serious e | none  | 40  | 39  | -  | MD **1.26 lower**(1.95 lower to 0.57 lower)  | ⨁◯◯◯VERY LOW  | IMPORTANT  |
| **MOCA** |
| 1  | randomised trials  | serious a | not serious  | not serious  | serious e | none  | 45  | 45  | -  | MD **3.39 higher**(1.04 higher to 5.74 higher)  | ⨁⨁◯◯LOW  | IMPORTANT  |
| **ADL** |
| 5  | randomised trials  | not serious  | serious b | not serious  | not serious  | none  | 251  | 250  | -  | MD **14.04 higher**(7.23 higher to 20.86 higher)  | ⨁⨁⨁◯MODERATE  | IMPORTANT  |
| **MRS** |
| 2  | randomised trials  | serious a | serious d | not serious  | not serious  | none  | 73  | 73  | -  | MD **0.61 lower**(0.81 lower to 0.42 lower)  | ⨁⨁◯◯LOW  | IMPORTANT  |

**CI:** Confidence interval; **OR:** Odds ratio; **MD:** Mean difference

#### Explanations

a. The included studies did not give specific information in terms of blinding and allocation concealment.

b. The presence of considerable heterogeneity in the included studies (I-square value >75%).

c. Strongly suspect publication bias.

d. Heterogeneity test P value is very small.

e. Total number of participants not enough to provide a precise result.